Windecker, S

Gencer, B; Carballo, D; Nanchen, D; Koskinas, K; Klingenberg, R; Raeber, L; Auer, R; Carballo, S; Heg, D; Windecker, S; Luscher, T F; Matter, C M; Rodondi, N; Mach, F (21 October 2019). P1222Intensification of lipid lowering therapy before and after publication of the IMPROVE-IT trial: A temporal analysis from the SPUM-ACS cohort. European Heart Journal, 40(Supplement_1), p. 678. 10.1093/eurheartj/ehz748.0180

Denegri, A; Magnani, G; Rossi, V A; Raeber, L; Windecker, S; Gencer, B; Mach, F; Rodondi, N; Heg, D; Nanchen, D; Matter, C M; Luescher, T F (October 2019). P6440The perils of polyvascular disease with concomitant type 2 diabetes in a real-world cohort of patients with acute coronary syndrome. European Heart Journal, 40(Supplement_1), p. 4040. 10.1093/eurheartj/ehz746.1034

Obeid, S.; Von Eckardstein, A.E.; Denegri, A.D.; Bockhorn, Y.B.; Klingenberg, R.K.; Gencer, B.G.; Mach, F.M.; Raeber, L R; Windecker, S; Rodondi, N R; Nanchen, D.N.; Matter, C.M.; Luescher, T.F. (29 August 2017). P3651 Risk of death and cardiovascular events among patients presenting with acute coronary syndrome: the evolving role of cystatin C, NGAL and galectin-3 as prognostic biomarkers. European Heart Journal, 38(suppl_1), ehx504.P3651. Oxford University Press 10.1093/eurheartj/ehx504.P3651

Canivell, S.; Muller, O.; Gencer, B.; Heg, D; Klingenberg, R.; Raeber, L; Carballo, D.; Matter, C.M.; Luescher, T.F.; Windecker, S; Mach, F.; Rodondi, N; Nanchen, D. (August 2017). 2191 Impact of non-cardiovascular multimorbidity after acute coronary syndrome. European Heart Journal, 38(suppl_1), ehx502.2191. Oxford University Press 10.1093/eurheartj/ehx502.2191

Koskinas, K C; Gencer, B.; Raeber, L; Karagiannis, A.; Nanchen, D.; Carballo, D.; Carballo, S.; Klingenberg, R.; Heg, D; Matter, C.; Luscher, T.F.; Rodondi, N; Windecker, S; Mach, F. (August 2017). P169 Eligibility for PCSK9 inhibitors according to ESC/EAS and ACC recommendations after acute coronary syndromes. European Heart Journal, 38(suppl_1), ehx501.P169. Oxford University Press 10.1093/eurheartj/ehx501.P169

Büllesfeld, L; Heg, Dik; Windecker, S (2012). Reply: Why Permanent Pacemaker Implantation After Transcatheter Aortic Valve Implantation Does Not Affect Long-Term Clinical Outcome. Journal of the American College of Cardiology, 60(22), pp. 2340-2341. New York, N.Y.: Elsevier

Carrel, T; Wenaweser, P; Reineke, S; Simon, R; Eberle, B; Windecker, S; Huber, C (2012). Worldwide first surgical implantation of a transcatheter valved stent in mitral position. Cardiovascular medicine, 15, pp. 202-05. Basel: EMH Swiss Medical Publishers Ltd

Stortecky, S; Wenaweser, P; Windecker, S (2012). Transcatheter aortic valve implantation and cerebrovascular accidents. EuroIntervention, 8(Q), Q60-Q69. Toulouse: Europa Digital & Publishing 10.4244/EIJV8SQA11

Binder, R; Khattab, A; Windecker, S; Meier, B (2012). Nachsorge nach interventionellem PFO-Verschluss. In: , (ed.) Das persistierende Foramen ovale (pp. 85-9). Bremen et al.: UNI-MED

Garg, S; Räber, L; Serruys, P; Windecker, S (2012). Coronary Artery Stents. In: Eeckhout E, Serruys P (ed.) Percutaneous Interventional Cardiovascular Medicine: The PCR-EAPCI Textbook (pp. 51-144). Toulouse, France: PCT Europa Edition

Khattab, A; Binder, R; Windecker, S; Meier, B (2012). Ergebnisse des interventionellen PFO-Verschlusses. In: , (ed.) Das persistierende Foramen ovale (pp. 75-83). Bremen et al.: UNI-MED

Pilgrim, T; Windecker, S (2012). Stents and Stent Thrombosis. In: Mukherjee D, Cho L (ed.) Interventional Cardiology. 1001 Questions: An Interventional Cardiology Board Review (pp. 223-32). Lippincott Williams & Wilkins a Wolters Kluwer business, Philadelphia

Nietlispach, F; Gloekler, S; Khattab, A; Pilgrim, T; Schmid, M; Wenaweser, P; Windecker, S; Meier, B (2012). Percutaneous left atrial appendage closure. European geriatric medicine, 3(5), pp. 308-311. Amsterdam: Elsevier 10.1016/j.eurger.2012.03.012

Perk, J; De Backer, G; Gohlke, H; Graham, I; Reiner, Z; Verschuren, M; Albus, c; Benlian, P; Boysen, G; Cifkova, R; Deaton, C; Ebrahim, S; Fisher, M; Germano, G; Hobbs, R; Hoes, A; Karadeniz, S; Mezzani, A; Prescott, E; Ryden, L; ... (2012). European guidelines on cardiovascular disease prevention in clinical practice (version 2012). European Heart Journal, 33(13), pp. 1635-1701. Oxford: Oxford University Press 10.1093/eurheartj/ehs092

Praz, F; Beney, S; Wahl, A; Windecker, S; Meier, B (2012). Long-term follow-up after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism in elderly patients (≥ 70 years). European geriatric medicine, 3(1), pp. 23-27. Amsterdam: Elsevier 10.1016/j.eurger.2011.12.008

Puricel, S; Schoepke, L; Togni, M; Oberhänsli, M; Moschovitis, A; Meier, B; Windecker, S (2012). Balloon angioplasty using the “GRIP™” scoring balloon for treatment of coronary in-stent restenosis. Immediate and 12-month clinical outcomes. Cardiovascular medicine, 15, pp. 354-61. Basel: EMH Swiss Medical Publishers Ltd

Remondino, A; Seiler, C; Meier, P; Rakhit, R; Wustmann, K; Zbinden, R; Zbinden, S; Windecker, S; Togni, M; Wenaweser, P; Meier, B; Eberli, F (2011). Collateral function changes during primary percutaneous coronary intervention in acute myocardial infarction. Cardiovascular medicine, 14, pp. 119-26. Basel: EMH Swiss Medical Publishers Ltd

Buellesfeld, L; Windecker, S (2011). Update on transcatheter aortic valve implantation registries and studies Minerva Cardioangiol. Minerva cardioangiologica, 59, pp. 419-30. Torino: Minerva Medica

Di Mario, C; Windecker, S; Fajadet, J (2011). Continuity and innovation: the yin and yang of interventional cardiology. EuroIntervention, 7, pp. 425-7. Toulouse: Europa Digital & Publishing

Khattab, A A; Windecker, S (2010). Drug-eluting stents: limitations of early generation and progress with newer generation devices. Minerva medica, 101(1), pp. 9-23. Torino: Minerva Medica

Matter, C; Klingenberg, R; Templin, C; Altwegg, L; Räber, L; Carballo, D; Auer, R; Landmesser, U; Maier, W; Windecker, S; Jüni, P; Mach, F; Keller, PF; Rodondi, N; Lüscher, TF (2010). Inflammation and acute coronary syndromes (ACS) a clinical research network funded by the Swiss National Science Foundation. Cardiovascular medicine, 13, pp. 31-34. Muttenz: EMH Swiss Medical Publishers Ltd

Pilgrim, T; Wenaweser, P; Windecker, S; Meier, B (2010). Comprehensive one stop-shop percutaneous cardiac intervention. Cardiovascular medicine, 13, pp. 171-173. Basel: EMH Swiss Medical Publishers Ltd

Pilgrim, T; Roffi, M; Pedrazzini, G; Kaiser, C; Stauffer, JC; Rickli, H; Windecker, S (2010). Medikamenten-freisetzende Ballonkatheter (Drug-Eluting Balloons) in der Behandlung der Koronaren Herzkrankheit. Stellungnahme der Arbeitsgruppe Interventionelle Kardiologie und Akute Koronarsyndrome der SGK. Cardiovascular medicine, 13(6), pp. 214-218. Basel: EMH Swiss Medical Publishers Ltd

Pilgrim, T; Wenaweser, P; Windecker, S (2010). Comparing Outcomes between surgical aortic valve replacement and transcatheter aortic valve implantation. Journal of interventional cardiology, 2, pp. 681-694. Hoboken, N.J.: Wiley

Pilgrim, T; Windecker, S (2010). Koronare Revaskularisation (Teil 1): Was ist beim akuten Koronarsyndrom perkutan möglich? Cardiovasc, 9 Prime Public Media AG

Pilgrim, T; Windecker, S (2010). Perkutane Revaskularisation (Teil 2): Was ist bei der stabilen koronaren Herzkrankheit möglich? Cardiovasc, 9 Prime Public Media AG

Pilgrim, T; Windecker, S (2010). Primary Percutaneous Coronary Intervention: Culprit-Vessel versus Multivesses Intervention. In: S Brecker, M Rothman (ed.) Clinical Guide to Primary Angioplasty (pp. 77-89). Informa Healthcare, United Kingdom

Maeder, M; Windecker, S; Roffi, M; Kaiser, C; Stauffer, JC; Pedrazzini, G; Rickli, H (2010). Interventional Cardiology in Switzerland during the Year 2007. Cardiovascular medicine, 13, pp. 18-24. Muttenz: EMH Swiss Medical Publishers Ltd

Pilgrim, T; Windecker, S (2010). Was ist beim perkutanen Koronarsyndrom perkutan möglich. Cardiovasc, 9 Prime Public Media AG

Pilgrim, T; Windecker, S (2010). Was ist bei der stabilen koronaren Herzkrankheit perkutan möglich. Cardiovasc, 9 Prime Public Media AG

Cook, S; Windecker, S (2010). Coronary artery stenting. In: Mukherjee, Bates (ed.) Cardiovascular Catheterization and Intervention. Informa Healthcare

Wenaweser, P; Windecker, S (2010). Transcatheter Aortic Valve Implantation With the Medtronic CoreValve Revalving System. In: , (ed.) Percutaneous Cardiac Interventions. Tips and Tricks of new techniques beyond stenting. PCR Publishing, Toulouse, France

Meliga, E; Garcia-Garcia, H M; Valgimigli, M; Chieffo, A; Biondi-Zoccai, G; Maree, A O; Gonzalo, N; Cook, S; Marra, S; Moretti, C; De Servi, S; Palacios, I F; Windecker, S; van Domburg, R; Colombo, A; Sheiban, I; Serruys, P W (2009). Impact of drug-eluting stent selection on long-term clinical outcomes in patients treated for unprotected left main coronary artery disease: the sirolimus vs paclitaxel drug-eluting stent for left main registry (SP-DELFT). International journal of cardiology, 137(1), pp. 16-21. Amsterdam: Elsevier 10.1016/j.ijcard.2008.06.006

Cook, S; Windecker, S (2009). Revascularisation of coronary artery disease in patients with diabetes mellitus. Swiss medical weekly, 139(45-46), pp. 654-64. Muttenz: EMH Schweizerischer Ärzteverlag

Pilgrim, T; Windecker, S (2009). Drug-eluting stent thrombosis. Minerva cardioangiologica, 57(5), pp. 611-20. Torino: Minerva Medica

Wahl, A; Kunz, M; Moschovitis, A; Nageh, T; Schwerzmann, M; Seiler, C; Mattle, H P; Windecker, S; Meier, B (2008). Long-term results after fluoroscopy-guided closure of patent foramen ovale for secondary prevention of paradoxical embolism. Heart, 94(3), pp. 336-41. London: BMJ Publishing Group 10.1136/hrt.2007.118505

Mazzolai, L; Albisetti, M; Asmis, L; Baumgartner, I; Bounameaux, H; Dörffler-Melly, J; Husmann, M; Kucher, N; Spirk, D; Windecker, S; Wuillemin, WA (2007). Einfach und schnell zu den Empfehlungen bei Prophylaxe und Therapie venöser Thrombembolie. Schweizerisches Medizin-Forum SMF / Swiss medical forum / Forum médical suisse FMS(7), pp. 864-865. Basel: EMH Editores Medicorum Helveticorum

Cutlip, D.E.; Windecker, S; Mehran, R; Boam, A; Cohen, DJ; van Es, GA; Steg, PG; Morel, MA; Mauri, L; Vranckx, P; McFadden, E; Lansky, A; Hamon, M; Krucoff, MW; Serruys, PW; Academic, Research Consortium (2007). Clinical end points in coronary stent trials: a case for standardized definitions. Circulation, 115(17), pp. 2344-51. Baltimore, Md.: Lippincott Williams & Wilkins 10.1161/CIRCULATIONAHA.106.685313

Meier, B; Sousa, E; Guagliumi, G; Van den Branden, F; Grenadier, E; Windecker, S; te Riele, H; Voudris, V; Eltchaninoff, H; Lindvall, B; Snead, D; Talen, A; SVELTE, Study Group (2006). Sirolimus-eluting coronary stents in small vessels. American Heart Journal, 151(5), 1019.e1-7. St. Louis, Mo.: Elsevier 10.1016/j.ahj.2006.02.025

Stettler, C; Allemann, S; Egger, M; Windecker, S; Meier, B; Diem, P (2006). Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials. Heart, 92(5), pp. 650-7. London: BMJ Publishing Group 10.1136/hrt.2005.070698

Chatterjee, T; Schroeder, Verena; Windecker, S; Meier, B; Kohler, H P (2003). Venous and intracoronary factor XIII A-subunit antigen and activity levels are not associated with extent of coronary artery disease. Journal of thrombosis and haemostasis, 1(4), pp. 861-863. Blackwell 10.1046/j.1538-7836.2003.t01-8-00115.x